t r a c t
In February the World Health Organisation (WHO) recommends influenza viruses to be included in influenza vaccines for the forthcoming winter in the Northern Hemisphere. These recommendations are based on data collected by National Influenza Centres (NICs) through the WHO Global Influenza Surveillance and Response System (GISRS) and a more detailed analysis of representative and potential antigenically variant influenza viruses from the WHO Collaborating Centres for Influenza (WHO CCs) and Essential Regulatory Laboratories (ERLs). This article provides a detailed summary of the antigenic and genetic properties of viruses and additional background data used by WHO experts during development of the recommendations of the 2013-2014 Northern Hemisphere influenza vaccine composition.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
In contrast to many other vaccines, influenza vaccines are frequently updated to be effective against newly evolving human influenza viruses that are likely to circulate in the following influenza season. WHO convenes technical consultations (vaccine composition meetings (VCM)) twice a year to provide guidance to national public health authorities and vaccine manufacturers on the viruses to be included in trivalent or quadrivalent influenza vaccines for the following influenza seasons in the Northern and Southern Hemispheres. The committee assembled by WHO comprises representatives from six WHO CCs (Melbourne, Australia; Beijing, China; Tokyo, Japan; London, United Kingdom; Atlanta, USA; Memphis, USA) and four ERLs (Therapeutic Goods Administration (TGA), Australia; National Institute of Infectious Diseases (NIID), Japan; National Institute for Biological Standards and Control (NIBSC), UK; Food and Drug Administration (FDA), USA), with observers from H5 Reference Laboratories, WHO NICs and other expert groups. The committee analyses data that encompass the epidemiological, antigenic and genetic characteristics of the most recently circulating influenza viruses as well as preliminary vaccine effectiveness data where they are available. In addition, panels of antisera from individuals (children, adults and elderly) who received seasonal trivalent inactivated vaccines are tested to measure levels of antibodies to currently circulating influenza viruses. The committee assesses which viruses are likely to predominate in the forthcoming season and recommends vaccine candidates accordingly. With the WHO recommendations in mind, national and international regulatory agencies should determine which influenza viruses are best suited for influenza vaccines to be licensed in their country.
In the present report we describe the basis for the selection of 
Influenza activity, September 2012-February 2013
Influenza activity between the previous WHO VCM for seasonal influenza in September 2012 [1] and the VCM in February 2013 was reported by NICs and collated in the WHO FluNet database (see http://www.who.int/flunet). During this period, influenza activity was reported worldwide. Influenza activity in countries in the Northern Hemisphere was low in September and October but increased activity was reported in North America in November, in Europe from December onwards and in a number of countries in Asia in December or January. In the Southern Hemisphere, influenza activity generally declined from September onwards while in tropical areas many countries reported outbreaks of varying intensity.
Regional A(H1N1)pdm09 activity was reported by a few countries in Asia, Central and South America as well as central Africa. In January, many countries in northern, eastern and central Europe and northern Africa (Algeria) had regional and widespread outbreaks. Localised and sporadic activity was also reported in many other countries in northern Africa, Asia and North America.
Influenza A(H3N2) virus activity increased in November and caused widespread outbreaks in Canada and the United States of America where it was the predominant circulating virus subtype. In Asia, regional outbreaks occurred in Cambodia from September to November. Regional and widespread outbreaks were reported in the Republic of Korea and Japan in January. Low-level activity was reported in Europe from September to November but increased during December and January in many countries. In northern Africa, activity increased in January with widespread outbreaks reported in Algeria. Sporadic and localised A(H3N2) activity was also reported in Oceania, central (Cameroon) and southern Africa and a number of countries in South America.
Influenza B virus activity increased in North America from November with regional outbreaks reported by Mexico and the United States of America and was predominant in Mexico. In Europe, widespread outbreaks were reported in many countries in January. In Asia activity was generally low. Localised and sporadic B activity was also reported by a number of countries in Africa, Oceania and South America. Influenza activity maps (maximum level of activity shown) for the period August 2012-January 2013 along with graphs showing the number of influenza viruses detected, typed and subtyped by the GISRS laboratories from 2010 to 2013 are presented in Fig. 1 . At the time of the VCM, data collected from the GISRS laboratory network showed that, of the influenza viruses collected from September 2012 to February 2013, approximately 92,298 (77%) were type A and 27,695 (23%) type B; of the type A viruses 14,306 (15.5%) were A(H1N1)pdm09, 47,213 (51.2%) were A(H3N2) and 30,779 (33.3%) were not subtyped.
Overview of antigenic and genetic characteristics of the viruses
For the Consultation, WHO CCs performed detailed antigenic analyses on 3147 influenza viruses (Table 1) . Viruses were collected from September 2012 to the beginning of February 2013 and recovered from either clinical specimens or virus isolates provided by NICs and other laboratories within and outside GISRS. Antigenic characterisation was carried out predominantly by haemagglutination inhibition (HI) assays using viruses isolated and propagated in either mammalian tissue culture cells (most frequently MadinDarby canine kidney cells (MDCK) or MDCK-SIAT-1 cells, the latter engineered to express increased levels of ␣-2,6 sialyl transferase [2] ) or in embryonated hens' eggs. HI assays using turkey or guinea pig red blood cells (RBC) were performed to compare the reactivity of cultured viruses with post-infection ferret antisera raised against egg-or cell-propagated reference viruses [3] . A subset of viruses also underwent genetic characterisation. Genetic analyses were focused on the sequencing of the haemagglutinin (HA) and neuraminidase (NA) genes, with matrix (M) gene or full genome sequencing performed on a smaller subset of viruses. HA gene sequencing supports HI assay results by providing the molecular basis for any observed antigenic variation in circulating influenza viruses, compared to current vaccine viruses, and phylogenetic analysis of HA and NA genes defines the genetic relatedness of circulating viruses within their particular A-subtype or B-lineage. The initial phylogenetic tree of the HA1 domain nucleotide sequences of each A-subtype or B-lineage was constructed with the PhyML software package version 3.0 [4] using GTR + I + 4. For this analysis the general time-reversible model with the proportion of invariant sites and the gamma distribution of among-site rate variation with four categories was estimated from the empirical data, determined by ModelTest [5] as the evolutionary model. GARLI v0.961 [6] was run on the best tree from PhyML for 2 million generations to optimise tree topology and branch lengths for each virus A-subtype or B-lineage. The virus gene sequence accession numbers and their originating laboratories used in this report are listed in Table S1 . A combination of antigenic and genetic data is routinely used to identify emergent antigenic variants. Antigenic cartography [7] was used to visualise the HI data. As discussed previously, the behaviour of A(H3N2) viruses in HA and HI assays has changed in recent years and their antigenic analyses have become more complex [8] . In particular, guinea pig RBC are now preferred for antigenic characterisation of current A(H3N2) viruses in HA and HI assays. To control for the possible participation of the virus NA in the agglutination of RBC, HI assays can also be performed in the presence of oseltamivir [9] . Virus neutralisation (plaque reduction and microneutralisation) assays were performed in addition to HI tests for a subset of A(H3N2) viruses and a small number of A(H1N1)pdm09 viruses.
In addition to antigenic studies using post-infection ferret antisera, human serum panels obtained pre-and post-vaccination with seasonal influenza vaccine formulations were used to assess current vaccine coverage against representative recently circulating viruses. Serum panels for adults, elderly and paediatric populations received from Australia, China, Japan, the UK and the USA were tested where available.
A(H1N1)pdm09 viruses
Only a relatively small number of A(H1N1)pdm09 viruses (392) were subjected to HI analysis by the WHO CCs from September 2012 to February 2013. The majority of these viruses remained antigenically closely related to the vaccine virus A/California/7/2009 based on assays with post-infection ferret antisera and only 3.3% of these viruses had reduced titres of 8-fold or greater compared to titres against the homologous virus (Table 1) .
A high resolution phylogenetic tree of the HA genes was constructed and included 379 A(H1N1)pdm09 isolates collected through GISRS since February 2012 as shown in Fig. S1 . While the phylogenetic tree of the A(H1N1)pdm09 HA gene can be divided into eight major genetic groups, the majority of viruses analysed for the VCM belonged to group 6 with the signature amino acid (AA) substitutions D97N, S185T and S451N in HA1 (Fig. 2, Fig.  S1 ). Fewer viruses belonged to group 7 (signature AA substitutions N97D and A197T in HA1) were still present but fewer in number than in the previous reporting period. Viruses from the other groups were rare with the exception of a small number of viruses from Japan, Norway and Africa which belonged to subgroup 8 ( Fig. S1 ) and a group of viruses that appeared to be circulating [5] . GARLI v0.961 [6] was run on the best tree from PhyML for 2 million generations to optimise tree topology and branch lengths. Viruses are colour-coded by month of collection as follows: October 2012 in green, November 2012 in orange, December 2012 in purple and January 2013 in red. The current vaccine virus is shown in capital letters. Genetic groups are labelled 5-8. exclusively in West Africa, as represented by A/Dakar/20/2012 (Fig. 2) . AA substitutions in the 153-157 region of HA1 were identified in a number of cell-or egg-propagated A(H1N1)pdm09 viruses that had low reactivity to ferret antisera raised against A/California/7/2009 and some viruses had nucleotide polymorphism in their HA sequences encoding these amino acids (for example A/Beijing-Huairou/SWL11293/2013, Table 2 ). Generally, these 153-157 substitutions/polymorphisms were not detected in the original clinical samples, indicating that they had arisen or become predominant during adaptation to culture. Sequences of isolates with substitutions at positions 153-157 in the HA were distributed throughout the phylogenetic tree and have appeared in nearly all genetic groups in the past (data not shown). Full genome sequencing was carried out on viruses from several geographic regions and no evidence of reassortment with co-circulating A(H3N2) viruses or other viruses was obtained (data not shown). Antigenic cartography illustrated that the majority of A(H1N1)pdm09 isolates continued to be antigenically similar to A/California/7/2009 and clustered together, demonstrating little antigenic diversity during this period or since 2009 (Fig. S2) . In contrast many of the viruses with AA substitutions in the 153-157 region of HA1 clustered together at some antigenic distance from the vaccine virus A/California/7/2009 and most other recent isolates (Fig. S2, Table 2 ).
Vaccines containing the A/California/7/2009 (H1N1pdm09) antigen stimulated anti-HA antibodies of similar geometric mean HI titres to the vaccine virus and the majority of representative A(H1N1)pdm09 isolates tested. Fig. S3 summarises human serology following seasonal influenza vaccination. Only a few A(H1N1)pdm09 viruses showed a significant (>50%) reduction in geometric mean titres (GMT) in HI tests with human sera from vaccinees who received vaccines containing A/California/7/2009. In some panels reductions were seen against egg-derived A/Bangladesh/2021/2012 virus which has an N156S substitution in HA1, a change known to alter the antigenic properties of H1N1pdm09 viruses, as described above. Although reactivity was also reduced against some cell-propagated viruses, such as [7] . A/Stockholm/34/2012, no reduction was seen in HI studies of this virus using post-infection ferret antiserum. Based on analyses of data presented at the VCM, it was concluded that the observed genetic diversity of A(H1N1)pdm09 viruses had not resulted in changes in their antigenic properties and that A/California/7/2009, remained appropriate for use in the 2013-2014 Northern Hemisphere vaccine.
A(H3N2) viruses
The majority (61.1%) of seasonal influenza viruses analysed by the WHO CCs during the September 2012-February 2013 period were influenza A(H3N2) viruses (Table 1) . The WHO CCs used a variety of antigenic assays to analyse the 1923 A(H3N2) viruses collected and showed that the vast majority of these viruses were antigenically similar to MDCK-propagated A/Victoria/361/2011 A(H3N2) virus, with less than 1% being low reacting (those with 8-fold or lower titres compared to the homologous titre; Table 1 the homologous antigen. An HI assay performed in the presence of 20 nM oseltamivir with guinea pig RBC (Table S2 ) and virus plaque-reduction (Tables S3 and S4 ) or microneutralisation (Table  S5 ) assays showed similar results.
Antigenic cartography showed that recently circulating cell-propagated A(H3N2) viruses clustered around both the A/Victoria/361/2011 and the A/Texas/50/2012 MDCK-propagated viruses with the equivalent egg-propagated viruses being placed some distance away (Fig. 3) . It was concluded that while the majority of A(H3N2) viruses that circulated from September 2012 to February 2013 were antigenically related to the A/Victoria/361/2011 MDCK-propagated virus, they were better inhibited or neutralised by ferret antisera raised against egg-propagated A/Texas/50/2012 than by those raised against egg-propagated A/Victoria/361/2011.
A simple phylogenetic tree for the HA of A(H3N2) viruses is presented in Fig. 4 and a high resolution tree with HA sequences of 872 A(H3N2) viruses collected through GISRS since February 2012 is shown in Fig. S4 .
The majority of circulating viruses belonged to genetic group 3 with the signature AA substitution V223I. The group 3 viruses currently can be further divided into subgroups 3A, 3B and 3C. Subgroup 3A viruses carry AA substitutions at N144D (leading to the loss of a potential glycosylation site) and N145S in HA1. Subgroups 3B and 3C isolates carry AA substitutions A198S and N312S, while 3C viruses carry additional AA substitutions at S45N (leading to the gain of a possible glycosylation site) and T48I in HA1. Many subgroup 3C viruses also carry an additional AA substitution at N145S along with a further substitution at T128A, which results in the loss of a glycosylation site, and R142G. Groups 5 and 6 have signature AA substitutions D53N, Y94H, I230V and E280A in HA1, with group 6 isolates carrying an additional AA substitution S199A. Most of the A(H3N2) viruses collected since September 2012 fell into genetic subgroup 3C represented by A/Victoria/361/2011 with a small number, mainly from the US and Europe, belonging to subgroup 3A and group 5. Just a few viruses fell into subgroup 3B and group 6 (Fig. 4, Fig. S4 ).
Some isolates from North America, Europe and Asia belonged to groups 5 and 6, which have signature AA substitutions D53N, Y94H, I230V and E280A in HA1, with group 6 isolates carrying an additional AA substitution S199A. Viruses with low HI titres to post-infection ferret antisera raised against cell-propagated A/Victoria/361/2011 viruses were scattered throughout the HA tree and did not form monophyletic groups or share common AA substitutions. Genetic analysis of the HA sequences of several egg-propagated A/Victoria/361/2011-like viruses were compared in order to see if low HI titres might be associated with amino acid substitutions linked to adaptation to growth in eggs. A number of such substitutions were noted in the HA of the initial egg-propagated A/Victoria/361/2011 wild-type virus, including a H156R substitution. A subsequent R156Q change was acquired in the high growth reassortants IVR-165 and X221, although H156R was retained in the reassortant NIB-79. Changes in amino acid sequence in this area of the HA of A(H1N1)pdm09 viruses have been shown to alter their antigenic properties and, based on the ferret and human serology obtained for the egg-propagated A/Victoria/361/2011 virus, such substitutions may also have altered the antigenicity of this virus. Some egg-propagated viruses genetically similar to A/Victoria/361/2011, such as A/Texas/50/2012, did not have similar adaptive substitutions in the 153-157 HA region. Egg-propagated A/Hawaii/22/2012 and the high growth reassortants made from this virus, X225 and X225A, had the substitution L157S and in HI assays antisera raised against A/Hawaii/22/2012 recognised the majority of test viruses with titres reduced more than 4-fold compared to the homologous virus (Table 3) .
Vaccines containing influenza A/Victoria/361/2011 (H3N2)-like antigen stimulated anti-HA antibodies in all age groups that had reduced geometric mean HI titres to the majority of cell-propagated A(H3N2) viruses compared to the egg-propagated vaccine virus or other egg-propagated recent viruses (Fig. S5) . The average reductions in HI GMT against cell-propagated A(H3N2) viruses compared to the egg-propagated vaccine virus were 66% for adults, 68% for the elderly and 64% for children.
Based on surveillance data available in February 2013, it was concluded that the A(H3N2) component of the 2012-2013 Northern Hemisphere influenza vaccine should remain as a A/Victoria/361/2011-like virus. However it was stipulated that the like virus should be antigenically like the cell-propagated prototype virus. For this reason a new vaccine virus A/Texas/50/2012 and its reassortants, X-223 and X223A, were recommended for use in vaccines that are based on egg propagation.
Influenza B viruses
From September 2012 to February 2013, 832 influenza B viruses were analysed by WHO CCs. Of these 435 were B/Victoria-lineage viruses (52.3%) and 397 were B/Yamagata-lineage viruses (47.7%). The analyses of influenza B viruses by HI assays continued to demonstrate that antisera raised in ferrets infected with egg-grown B viruses may react poorly with cell-grown B viruses, prompting the extensive use of cell-grown viruses for antiserum production in ferrets for use in HI assays [8] . In addition, influenza B viruses often generate antisera with lower titres than those raised against influenza A viruses and some WHO CCs undertake additional boosting of ferrets, which can potentially broaden the cross-reactivity of the antibody responses.
For the B/Victoria-lineage viruses collected from September 2012 to February 2013, the combined HI data from all WHO CCs showed approximately 11% of isolates to have reduced HI titres with post-infection ferret antiserum raised against B/Brisbane/60/2008, a previously recommended vaccine virus of the B/Victoria-lineage, or cell-propagated viruses genetically similar to it (Table 1) . During this period few differences were seen in HI reactivity (Table 4 ) or in antigenic maps created from these data (Fig. S6) .
The vast majority of HA genes from recent B/Victoria-lineage viruses fell into genetic group 1 represented by B/Brisbane/60/2008 with signature AA substitutions N75K, N165K and S172P in HA1 (Fig. 5) . A high resolution tree constructed with HA sequences from 357 B/Victoria-lineage isolates collected through GISRS since February 2012 is shown in Fig. S7 and illustrates the high predominance of recent viruses in genetic group 1. Genetic subgroups within group 1, 1A and 1B, have been identified and are associated with the amino acid substitution L58P in HA1. The majority of viruses were in subgroup 1A with leucine at residue 58 of HA1. Some of the recent virus isolates, mainly from China, that fell into subgroup 1B had proline at residue 58 of HA1 and had NA genes from different groups of the B/Victoria lineage, namely HA genes from the B/Victoria-lineage subgroup 1B and NA genes from HA group 4 viruses (HA-1B/NA-4) with these intra-lineage reassortant viruses having the additional AA substitutions K272Q, E320K, D384N and A465T (the latter change leading to the gain of a potential glycosylation site) in the NA compared with viruses that carried both the HA and NA genes of genetic group 4. Viruses in a third small cluster within subgroup 1A carried the HA1 AA substitution V146I. An additional cluster within subgroup 1A has undergone intra-lineage reassortment inheriting the NA gene from isolates similar to those in HA group 3 (HA-1A/NA-3, represented by B/Uruguay/12/2008), but with additional AA substitutions L73F, S397R, M375K and A389T in the NA and another intra-lineage reassorted group with V15I in the HA1. The latter circulated recently in North America, Japan and Europe (Fig. S7 ).
For the B/Yamagata-lineage viruses collected from September 2012 to February 2013, the combined HI data from all WHO CCs showed that approximately 10% of the isolates had reduced HI titres (8-fold or greater compared to the homologous titre) with postinfection ferret antiserum raised against B/Wisconsin/1/2010, the previously recommended vaccine virus (Table 5) (Fig. S9) . Some serum panels gave significantly lower anti-HA antibody titres against genetic group 2 viruses than against genetic group 3 B/Yamagata-lineage viruses.
Based on the increasing proportion of B/Yamagata-lineage viruses, notably those falling within HA genetic group 2, in many parts of the world during the surveillance period and the antigenic differences observed between group 2 and group 3 B/Yamagatalineage viruses, it was concluded that a B/Massachusetts/2/2012-like virus (group 2; B/Yamagata-lineage) would be the most appropriate virus for trivalent vaccine compositions for use in the Northern Hemisphere for the 2013-2014 season. For quadrivalent influenza vaccines containing two influenza B viruses, it was recommended that the additional B virus be a B/Brisbane/60/2008-like virus of the B/Victoria lineage.
Antiviral resistance
The two classes of antiviral drugs currently licensed for the prevention and treatment of influenza are the adamantanes or M2 ion channel blockers (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, zanamivir and, in some countries, peramvir and laninamivir). All A(H1N1)pdm09 viruses screened for resistance markers carried the AA substitution S31N in the M2 protein associated with resistance to amantadine and rimantadine. There were sporadic detections A(H1N1)pdm09 viruses with reduced or highly reduced inhibition by oseltamivir due to the H275Y substitution in NA which has been associated with clinical resistance to this drug. The prevalence of resistance to oseltamivir remains low worldwide (1-2%, data not shown) and the available data for this consultation did not indicate a significantly increased proportion of oseltamivir resistant A(H1N1)pdm09 viruses isolated from patients not exposed to the drug compared to previous seasons (data not shown). All A(H1N1)pdm09 viruses were sensitive to zanamivir (data not shown). All but one A(H3N2) virus characterised, A/Cairo/136/2012 collected in December 2012 (S31), were resistant to adamantanes (based on the presence of the M2 protein AA substitution S31N) but all were sensitive to neuraminidase inhibitors oseltamivir and zanamivir (data not shown). Most influenza B viruses analysed were sensitive to oseltamivir and zanamivir: only one B isolate tested showed reduced inhibition by oseltamivir (data not shown).
